Ho Wai Derrick Siu

5PUBLICATIONS
17CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 16, 2026
Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program.

|Jan 08, 2024
Framework for the Use of External Controls to Evaluate Treatment Outcomes in Precision Oncology Trials.

Derrick H W Siu, Frank P Y Lin, Doah Cho

|Mar 25, 2022
Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future.

Lawrence Kasherman, Derrick Ho Wai Siu, Rachel Woodford

|Mar 24, 2022
Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review.

Derrick Ho Wai Siu, Robert Sean O'Neill, Carole A Harris

|Aug 19, 2021
MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG).

Ho Wai Derrick Siu, Niall Tebbutt, Lorraine Chantrill

Pageof 1

Frequent Collaborators

2 joint publications

Frank P Y Lin

1 joint publications

Doah Cho

1 joint publications

Gillian Z Heller

1 joint publications

David M Thomas